Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
long-acting beta2-adrenergic agonist |
| gptkbp:approvedBy |
1998
|
| gptkbp:ATCCode |
gptkb:R03AC13
|
| gptkbp:brand |
gptkb:Foradil
Oxis |
| gptkbp:CASNumber |
17351-75-6
|
| gptkbp:combines |
gptkb:budesonide
gptkb:beclometasone gptkb:mometasone |
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:eliminationHalfLife |
10 hours
|
| gptkbp:hasMolecularFormula |
C19H24N2O4
|
| https://www.w3.org/2000/01/rdf-schema#label |
eformoterol
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
beta2-adrenergic receptor agonist
|
| gptkbp:pregnancyCategory |
gptkb:C_(Australia)
|
| gptkbp:routeOfAdministration |
inhalation
|
| gptkbp:sideEffect |
headache
tremor palpitations |
| gptkbp:synonym |
gptkb:formoterol_fumarate
|
| gptkbp:usedFor |
asthma
chronic obstructive pulmonary disease |
| gptkbp:bfsParent |
gptkb:formoterol
|
| gptkbp:bfsLayer |
6
|